CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for hematologists, hematology-oncology fellows, medical oncologists and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma.
  
  LEARNING OBJECTIVES

  • Apply available clinical research findings in the formation of evidence-based therapeutic approaches for the treatment of newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
  • Consider the applicability of published Phase III clinical trial data documenting the benefit of CD79b-targeted therapy as a component of first-line treatment for patients with DLBCL.
  • Identify patients with R/R DLBCL for whom treatment with FDA-approved chimeric antigen receptor (CAR) T-cell therapies directed at CD19 may be appropriate.
  • Assess recently presented Phase III clinical trial data documenting the benefit of various CAR T-cell platforms as second-line therapy for patients with R/R DLBCL.
  • Review pivotal clinical trial findings leading to the FDA approvals of other novel compounds with unique mechanisms of action for R/R DLBCL.
  • Evaluate the mechanism of action of and available clinical trial findings with bispecific antibodies targeting CD20 x CD3 in patients with DLBCL in preparation for the potential commercial availability of these agents.
  • Develop supportive care strategies to minimize and manage the toxicities associated with available and emerging therapeutic strategies for patients with DLBCL.
  • Counsel appropriate patients on the potential benefits of participation in ongoing clinical research studies evaluating novel agents and strategies for DLBCL.

  

  ACCREDITATION STATEMENT
  In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Research To Practice. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
  
  PHYSICIAN CONTINUING MEDICAL EDUCATION
  Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CE activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
  
  Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CE ACTIVITY
  This CE activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SOHO2023/DLBCL/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Medical Learning Institute, Inc. (MLI) and Research to Practice (RTP) are committed to providing their participants with high-quality, unbiased and state-of-the-art education and adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by MLI and RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Matthew Lunning, DO
  Associate Professor of Medicine
  Medical Director, Cellular Therapy
  Associate Vice Chair of Research
  Assistant Vice Chancellor for Clinical Research
  Division of Hematology/Oncology
  Department of Internal Medicine
  University of Nebraska Medical Center
  Omaha, Nebraska
  
  Consulting Agreements: AbbVie Inc, Acrotech Biopharma, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, CRISPR Therapeutics, Daiichi Sankyo Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, MorphoSys, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Takeda Pharmaceuticals USA Inc.
  
  Laurie H Sehn, MD, MPH
  Chair, Lymphoma Tumour Group
  BC Cancer Centre for Lymphoid Cancer
  Clinical Professor of Medicine
  Division of Medical Oncology
  University of British Columbia
  Podcast Editor, Blood
  Vancouver, British Columbia, Canada
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Seagen Inc, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Genentech, a member of the Roche Group, Teva Oncology.
  
  MODERATOR
  Christopher R Flowers, MD, MS
  Chair ad Interim, Division of Cancer Medicine
  Professor, Department of Lymphoma/Myeloma
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Epizyme Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Spectrum Pharmaceuticals Inc; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor, ZIOPHARM Oncology Inc; Nonrelevant Financial Relationship: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, National Cancer Institute.
  
  All of the relevant financial relationships listed have been mitigated.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This CE activity is supported through educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc and AbbVie Inc, and Regeneron Pharmaceuticals Inc.
  
  Release date: October 12, 2023
  Expiration date: October 13, 2024
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.